
|Articles|August 1, 2002
Combination therapy lowers BPH progression risk by 67%
Orlando, FL-In a finding that will likely change the way physicianstreat patients with benign prostatic hyperplasia, the combination of twocommonly used drugs was shown to slow progression of the disease significantlybetter than placebo or either drug alone. In fact, treatment with the combinationof finasteride (Proscar) and doxazosin (Cardura) lowers the risk of BPHprogression by as much as 67% and the risk of urinary retention by as muchas 79%.
Advertisement
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Gemcitabine intravesical system delivers high 12-month DFS in papillary-only NMIBC
2
SYNC-T demonstrates high bone metastasis resolution in phase 1 cohort
3
Choosing salvage therapy after prostate cancer focal ablation
4
NDV-01 produces robust 9-month results in high-risk NMIBC
5


















